Abstracts:
Background: To compare the survival rate of
paclitaxel plus cisplatin (PC arm), paclitaxel plus
gemcitabine (PG arm) and gemcitabine plus
cisplatin (GC arm) in chemotherapy patients with
non resectable lung cancer.
Methods: This was a retrospective observational
study to evaluate chemotherapy response among
non resectable lung cancer patients with their
survival at cancer center CMH, Dhaka since 01
July 2013 to 31 March 2015. One hundred fifty-four
(154) non resectable lung cancer patients were
randomly divided into three groups, 50 patients in
PC arm, 51 patients in PG arm and 53 patients in
GC arm. In PC arm paclitaxel 175 mg/m2 (day 1)
with cisplatin 75mg/m2 (day 1), in PG arm
Paclitaxel 175 mg/m2 (day 1) with gemcitabine
1000 mg/m2 (days 1 and 8) and in GC arm
gemcitabine 1000 mg/m2 (days 1 and 8) with
cisplatin 100mg/m2 (day 1).
Results: Patients characteristics were similar
between the three groups. The overall response rate
was 40% in the PC arm,43.1% in the PG arm,
43.4% in the GC arm. The median survival time in
PC arm was 8.5 months, in PG arm was 8.8 months,
in GC arm was 9.2 months. The major side effect
was myelosuppression which accounts 71%
patients. The average treatment costs were 57% and
30% lower in PC arm as compared with GC and PG
arm respectively.
Conclusion: The median survival time, disease free
survival time and 1-year survival rate in PC, PG,
GC arms without significant difference. Treatment
were well tolerable; quality of life parameter was
mostly similar but paclitaxel with cisplatin was most
cost effective than others chemotherapy regimen.
Keywords: Non-resectable lung cancer, Paclitaxel,
Gemcitabine, Cisplatin, CMH.